November 2014
QPS360 Newsletter - 10th Edition
QPS Announces John Kolman as Executive Director and Head of Translational Medicine
The Big Picture: Why We Do What We Do - Antibody-Drug Conjugates (ADCs) in Action
AAALAC renewed QPS Austria's Full Accreditation
QPS Austria Scientists Publish on APPSL Mice as In Vivo Models for Alzheimer's disease
QPS Austria Generates Novel Tauopathy Screening Tools: Two Stable SHSY-5Y Cell Lines Overexpressing Full Length and Truncated Tau441
QPS/THI Webinar Series - Drug Transporter Strategies for Development of Small Molecules
Protein Binding Determination in In Vitro DDI Studies
A Tale of One Happy Client about Lightning-fast PK Data (i.e., QPS Doing What We Do)
Conducting ELISAs: are duplicates always necessary or do singlets suffice?
Translational Medicine
QPS Scientists Xun Wang & LingSing Chen publish editorial in Bioanalysis on the Challenges in Bioanalytical Assays for Biosimilars
Early Stage Clinical
QPS Netherlands Completes Complex First-in-Man Antibiotic Study for US Client in Record Time
Paul Lehman, QPS Vice President and Head of Dermal and Transdermal Research, Publishes on Estimating Skin Permeation Parameters
Late Stage Clinical
QPS Austria Webinar on Improving Patient Recruitment in Clinical Trials
Sampling the Airways and More: QPS Respiratory & Allergy News
Doug Kalman, Director of QPS MRA, publishes on a New Cream for the Treatment of Actinic Keratosis
Fresh from the Pipeline
Fresh from the pipeline
The Latest Original New FDA and EMA Drug Approvals  more
We Talk
Posters You Talk
Alzheimer's therapeutics targeting amyloid Beta 1-42 oligomers I: abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits - PLoS One  more
QPS Tube
QPS Tube
QPS Austria Webinar: Clinical Enrollment Management - How to Improve Processes in Clinical Trials  more
See You @
See You
16th Annual Early Clinical Development: Phase I & IIa Clinical Trials Conference
February 24 - 25, 2015
London, United Kingdom